Cargando…

Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan

Longer survival in patients with multiple myeloma (MM) after treatment with novel agents (NA) such as thalidomide, bortezomib, and lenalidomide may be associated with increased risks of developing second primary malignancies (SPM). Few data describe the risk of SPM in patients with MM in Asia. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yanfang, Hou, Hsin-An, Qiu, Hong, Tang, Chao-Hsiun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7463238/ https://www.ncbi.nlm.nih.gov/pubmed/32873831 http://dx.doi.org/10.1038/s41598-020-71243-z

Ejemplares similares

Treatment evolution and improved survival in multiple myeloma in Taiwan
por: Tang, Chao-Hsiun, et al.
Publicado: (2019)

Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan
por: Liu, Yanfang, et al.
Publicado: (2021)

Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients
por: Avivi, Irit, et al.
Publicado: (2023)

The growing burden of generalized myasthenia gravis: a population-based retrospective cohort study in Taiwan
por: Herr, Keira Joann, et al.
Publicado: (2023)

Second Primary Malignancy Risk in Multiple Myeloma from 1975 to 2018
por: Wang, Jing, et al.
Publicado: (2022)

Time Trend of Multiple Myeloma and Associated Secondary Primary Malignancies in Asian Patients: A Taiwan Population–Based Study
por: Tzeng, Huey-En, et al.
Publicado: (2013)

A population-based cohort study of the epidemiology of light-chain amyloidosis in Taiwan
por: Hou, Hsin-An, et al.
Publicado: (2022)

Healthcare resource utilization and costs associated with generalized myasthenia gravis: a retrospective matched cohort study using the National Health Insurance Research Database in Taiwan
por: Shen, Shih-Pei, et al.
Publicado: (2023)

Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups
por: Ailawadhi, S, et al.
Publicado: (2014)

Second Primary Malignancies and Myeloma Therapy: Fad or Fact?
por: Usmani, Saad Z.
Publicado: (2012)

Risks of all-cause death and completed suicide in patients with schizophrenia/schizoaffective disorder treated with long-acting injectable or oral antipsychotics: A population-based retrospective cohort study in Taiwan
por: Tang, Chao-Hsiun, et al.
Publicado: (2021)

Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics
por: Razavi, P, et al.
Publicado: (2013)

Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients
por: Rosenberg, A. S., et al.
Publicado: (2021)

Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis
por: Ragon, Brittany Knick, et al.
Publicado: (2023)

The Effects of Second Primary Malignancies and Frailty on Overall Survival and Mortality in Geriatric Turkish Patients with Multiple Myeloma
por: Ipek, Yildiz, et al.
Publicado: (2023)

Increased Risk of Second Primary Malignancy and Mortality at ten Years After Stem Cell Transplant for Multiple Myeloma: An Analysis of 14,532 Patients
por: Miles, Brittany, et al.
Publicado: (2021)

Multiple myeloma: family history and mortality in second primary cancers
por: Chattopadhyay, Subhayan, et al.
Publicado: (2018)

Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
por: Li, Ko-Jen, et al.
Publicado: (2021)

Increased risk of second primary malignancies following uterine cancer: a population-based study in Taiwan over a 30-year period
por: Lee, Kuan-Der, et al.
Publicado: (2015)

Persistence and Adherence to Biologics in Patients with Psoriasis in Taiwan: A New Biologics User Cohort Study
por: Huang, Yu-Huei, et al.
Publicado: (2022)

Risk of multiple myeloma and other malignancies among first‐ and second‐degree relatives of patients with multiple myeloma: A population‐based study
por: Langseth, Øystein O., et al.
Publicado: (2022)

Prevalence and Mortality-Related Factors of Multiple Myeloma in Taiwan
por: Chen, Jia-Hong, et al.
Publicado: (2016)

Autopsy Analysis may Contribute to Establish Actual Incidence of Second Primary Malignancies in Myeloma
por: Takano, Junichiro, et al.
Publicado: (2015)

Secondary Primary Malignancies in Multiple Myeloma: An Old Nemesis Revisited
por: Yang, Jay, et al.
Publicado: (2012)

Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
por: Charalampous, Charalampos, et al.
Publicado: (2023)

Comorbidity profiles of chronic migraine sufferers in a national database in Taiwan
por: Chen, Yong-Chen, et al.
Publicado: (2012)

Economic Burden of Atopic Dermatitis in Taiwan
por: LEE, Ellen M., et al.
Publicado: (2023)

Myeloma as a Second Malignancy following AML: Is a Second Allo Equivalent to Auto?
por: Bakanay, Sule Mine, et al.
Publicado: (2012)

Risk of Second Primary Cancers in Multiple Myeloma Survivors in German and Swedish Cancer Registries
por: Chen, Tianhui, et al.
Publicado: (2016)

Second Primary Conjunctival Squamous Cell Carcinoma on Multiple Myeloma: A Case Report
por: Jo, Woo Gyeong, et al.
Publicado: (2023)

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party
por: Hayden, Patrick J., et al.
Publicado: (2021)

Impact of Atopic Dermatitis on Work and Activity Impairment in Taiwan
por: CHAN, Tom C., et al.
Publicado: (2021)

Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial
por: Jones, J R, et al.
Publicado: (2016)

Increased incidence of second primary malignancy in patients with malignant astrocytoma: a population-based study
por: Wang, Wenming
Publicado: (2019)

Increased Risk of Second Primary Cancers Following Diagnosis of Malignant Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Population-Based Study
por: Huang, Xiaoyi, et al.
Publicado: (2019)

Role of Allogeneic Transplantation in Multiple Myeloma in the Era of New Drugs
por: Bruno, Benedetto, et al.
Publicado: (2010)

The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era
por: Resende Salgado, Lucas, et al.
Publicado: (2018)

Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma
por: Castella, Maria, et al.
Publicado: (2018)

Multiple myeloma and kidney transplantation: the beginning of a new era
por: Van den bosch, Ines, et al.
Publicado: (2019)

Bispecific Antibodies: A New Era of Treatment for Multiple Myeloma
por: Zhou, Xiang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7sqq973qfano6e7ml7t5vsvnip